In advanced esophageal squamous cell carcinoma, adding tislelizumab to first-line chemotherapy extends overall survival over three years of follow-up in a randomized phase 3 trial. The long-horizon data strengthen the durability profile of the regimen compared with chemotherapy alone. The result supports the increasing shift toward PD-1-based combinations as a backbone in upper GI oncology, particularly for patient populations with limited durable outcomes from chemotherapy. Longer follow-up also helps clarify whether treatment benefit persists beyond early response. Clinicians will now weigh the updated survival evidence against toxicity and sequencing considerations, while companies will likely use the dataset to inform future trial design in earlier lines and biomarker-enriched populations.
Get the Daily Brief